검색결과 : 12건
| No. | Article |
|---|---|
| 1 |
Loss of core fucosylation reduces low-density lipoprotein receptor expression in hepatocytes by inducing PCSK9 Kamada Y, Yamamoto A, Fujiyoshi A, Koseki M, Morishita K, Asuka T, Takamatsu S, Sakata Y, Takehara T, Taniguchi N, Miyoshi E Biochemical and Biophysical Research Communications, 527(3), 682, 2020 |
| 2 |
Evaluation of different IRES-mediated tricistronic plasmid designs for expression of an anti-PCSK9 biosimilar monoclonal antibody in CHO cells Cruz TA, Pinho MB, Castilho LR Biotechnology Letters, 42(12), 2511, 2020 |
| 3 |
New Insight on a Combination of Policosanol and 10-Dehydrogingerdione Phytochemicals as Inhibitors for Platelet Activation Biomarkers and Atherogenicity Risk in Dyslipidemic Rabbits: Role of CETP and PCSK9 Inhibition Elseweidy MM, Amin RS, Atteia HH, El-Zeiky RR, Al-Gabri NA Applied Biochemistry and Biotechnology, 186(4), 805, 2018 |
| 4 |
Hepatitis C virus regulates proprotein convertase subtilisin/kexin type 9 promoter activity Li ZB, Liu Q Biochemical and Biophysical Research Communications, 496(4), 1229, 2018 |
| 5 |
PCSK9 regulates the chemokine receptor CCR2 on monocytes Grune J, Meyborg H, Bezhaeva T, Kappert K, Hillmeister P, Kintscher U, Pieske B, Stawowy P Biochemical and Biophysical Research Communications, 485(2), 312, 2017 |
| 6 |
Atorvastatin and lovastatin, but not pravastatin, increased cellular complex formation between PCSK9 and the LDL receptor in human hepatocyte-like C3A cells Melendez QM, Wooten CJ, Lopez D Biochemical and Biophysical Research Communications, 492(1), 103, 2017 |
| 7 |
Removal of acidic residues of the prodomain of PCSK9 increases its activity towards the LDL receptor Holla OL, Laerdahl JK, Strom TB, Tveten K, Cameron J, Berge KE, Leren TP Biochemical and Biophysical Research Communications, 406(2), 234, 2011 |
| 8 |
Role of ubiquitination in PCSK9-mediated low-density lipoprotein receptor degradation Chen YQ, Wang H, Yu L, Yu XH, Qian YW, Cao GQ, Wang J Biochemical and Biophysical Research Communications, 415(3), 515, 2011 |
| 9 |
Secreted proprotein convertase subtilisin/kexin type 9 reduces both hepatic and extrahepatic low-density lipoprotein receptors in vivo Schmidt RJ, Beyer TP, Bensch WR, Qian YW, Lin AM, Kowala M, Alborn WE, Konrad RJ, Cao GQ Biochemical and Biophysical Research Communications, 370(4), 634, 2008 |
| 10 |
PCSK9 binds to multiple receptors and can be functionally inhibited by an EGF-A peptide Shan LX, Pang L, Zhang RM, Murgolo NJ, Lan H, Hedrick JA Biochemical and Biophysical Research Communications, 375(1), 69, 2008 |